Janux Therapeutics, Inc. (JANX)
NASDAQ:JANX
Want to see JANX full AI Analyst Report?
Top Page
Janux Therapeutics Inc
(NASDAQ:JANX)
Select Model
Select Model
Rating:49Neutral
Price Target:
$13.50
▼(-14.66% Downside)
Action:Reiterated
Date:06/13/26
The score is primarily weighed down by ongoing deep losses and a significant negative free cash flow profile, alongside weak technicals with the stock below key moving averages. These are partially offset by a strong, low-leverage balance sheet and improving TTM revenue growth, with governance events providing a small additional positive signal.
Positive Factors
Low leverage balance sheet
Very low debt-to-equity (~0.02) gives Janux durable financial flexibility for a clinical-stage biotech. Low leverage reduces near-term default risk, preserves capacity to fund trials or partner deals, and lengthens runway versus highly indebted peers while losses persist.
Negative Factors
Large and worsening cash burn
Consistent negative operating and free cash flow with a worsening TTM burn versus 2025 is a durable constraint. Persistent cash consumption forces recurring external financing or partnerships, raising dilution and execution risk and pressuring program continuity absent near-term non-dilutive inflows.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage balance sheet
Very low debt-to-equity (~0.02) gives Janux durable financial flexibility for a clinical-stage biotech. Low leverage reduces near-term default risk, preserves capacity to fund trials or partner deals, and lengthens runway versus highly indebted peers while losses persist.
Read all positive factors
Janux Therapeutics Inc (JANX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$826.95M
Dividend YieldN/A
Average Volume (3M)897.16K
Price to Earnings (P/E)―
Beta (1Y)1.48
Revenue Growth47.10%
EPS Growth-35.51%
CountryUS
Employees91
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.84
Shares Outstanding60,984,352
10 Day Avg. Volume717,785
30 Day Avg. Volume897,162
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)0.89
Price to Sales (P/S)85.51
P/FCF Ratio-10.27
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue37.26
Enterprise Value/Gross Profit68.81
Enterprise Value/Ebitda-7.16
Forecast
1Y Price Target
$31.42Price Target Upside98.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-1.77
Revenue Forecast (FY)$29.49M
Janux Therapeutics Inc Business Overview & Revenue Model
Company Description
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate t...
How the Company Makes Money
Janux Therapeutics does not sell approved commercial products and therefore does not generate product sales revenue. The company primarily funds operations through (1) capital raised in the public markets and other financing activities (e.g., equi...
Janux Therapeutics Inc Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
78
Positive
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 21.61M | 10.00M | 10.59M | 8.08M | 8.61M | 3.64M |
| Gross Profit | 11.70M | 7.97M | 8.53M | 6.13M | 7.77M | -22.60M |
| EBITDA | -112.45M | -111.60M | -66.93M | -56.34M | -62.22M | -32.56M |
| Net Income | -114.48M | -113.63M | -68.99M | -58.29M | -63.06M | -32.67M |
Balance Sheet | ||||||
| Total Assets | 1.03B | 1.01B | 1.06B | 380.41M | 364.01M | 379.82M |
| Cash, Cash Equivalents and Short-Term Investments | 956.39M | 966.57M | 1.03B | 344.03M | 327.02M | 374.96M |
| Total Debt | 21.57M | 22.14M | 23.02M | 24.54M | 25.30M | 194.00K |
| Total Liabilities | 86.69M | 50.70M | 38.73M | 36.06M | 43.27M | 13.50M |
| Stockholders Equity | 941.53M | 956.82M | 1.02B | 344.35M | 320.74M | 366.33M |
Cash Flow | ||||||
| Free Cash Flow | -78.49M | -83.28M | -44.17M | -52.42M | -49.37M | -18.46M |
| Operating Cash Flow | -77.55M | -82.23M | -43.81M | -50.58M | -42.92M | -16.98M |
| Investing Cash Flow | 47.70M | -300.98M | -258.02M | -41.19M | 58.27M | -340.96M |
| Financing Cash Flow | 7.94M | 4.95M | 713.24M | 59.55M | 500.00K | 386.52M |
Janux Therapeutics Inc Technical Analysis
Neutral
15.82
Price Trends
14.45
Negative
14.10
Negative
18.18
Negative
Market Momentum
-0.24
Positive
46.10
Neutral
52.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JANX, the sentiment is Neutral. The current price of 15.82 is above the 20-day moving average (MA) of 13.97, above the 50-day MA of 14.45, and below the 200-day MA of 18.18, indicating a bearish trend. The MACD of -0.24 indicates Positive momentum. The RSI at 46.10 is Neutral, neither overbought nor oversold. The STOCH value of 52.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JANX.
Janux Therapeutics Inc Risk Analysis
Janux Therapeutics Inc disclosed 79 risk factors in its most recent earnings report. Janux Therapeutics Inc reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Janux Therapeutics Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $3.75B | -21.43 | -32.55% | ― | ― | -7.28% | |
52 Neutral | $2.15B | -10.50 | -67.40% | ― | ― | -5.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $826.95M | -7.52 | -11.85% | ― | 47.10% | -35.51% | |
49 Neutral | $1.81B | -4.62 | -60.70% | ― | 23382.78% | 7.01% | |
45 Neutral | $2.46B | -6.63 | -74.86% | ― | ― | -85.06% | |
45 Neutral | $1.70B | -2.77 | -866.46% | ― | ― | 39.46% |
* Healthcare Sector Average
JANX
Janux Therapeutics Inc
13.74
-9.17
-40.03%
VRDN
Viridian Therapeutics
16.30
1.46
9.88%
PHVS
Pharvaris
31.54
14.98
90.46%
EWTX
Edgewise Therapeutics
35.21
20.72
143.00%
VERA
Vera Therapeutics
34.24
13.09
61.89%
BHVN
Biohaven Ltd.
12.14
-2.42
-16.62%
Janux Therapeutics Inc Corporate Events
Executive/Board ChangesShareholder Meetings
Janux Therapeutics Reports Results of 2026 Annual Meeting
Positive
Jun 12, 2026
On June 11, 2026, Janux Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, with a substantial majority of the 60,961,546 outstanding shares represented, underscoring strong shareholder engagement in corporate governance. Stockholders...
Executive/Board Changes
Janux Therapeutics Adjusts Board Class Structure for Director
Neutral
Apr 28, 2026
Janux Therapeutics, Inc. announced that on April 28, 2026, its board of directors rebalanced its classified structure by shifting director Eric Dobmeier from Class III, which had a term expiring at the 2027 annual stockholders’ meeting, to C...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.